- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01662713
Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (OFDI)
Study Overview
Detailed Description
Non-melanoma skin cancer (NMSC) is the most common cancer in the United States, with more than 750,000 diagnosed patients treated every year. Its prevalence and incidence have significantly increased over the past two decades and it has been estimated that 20% of all Americans will develop this type of cancer during their lifetime (Neville et al., 2007). Biopsy and surgical resection of NMSC can result in tissue mutilation and scaring. Therefore, there is a need for new imaging technologies that can be used to non-invasively guide biopsy and surgery.
Optical Frequency Domain Imaging (OFDI) is a second-generation imaging implementation of optical coherence tomography (OCT) developed at the Wellman Center. OFDI provides high-resolution three-dimensional imaging in tissue. It uses an interferometric depth-sectioning technique and employs a near-infrared light source. Through analysis of phase information in the recorded signal. OFDI can detect blood vessels within tissues and tumors. Importantly, OFDI-based vascular imaging can be performed without the need for exogenous contrast agents, making it relatively easy to deploy in clinical settings.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects with Fitzpatrick skin type I-VI
- Subjects with ages between 18 and 80 years of age
- Presence of at least one NMSC lesion
Exclusion Criteria:
- Subjects with active localized or systemic infections
- Subjects participating in potentially confounding clinical studies of investigational therapies, either drug or device.
- Subjects taking any topical/systemic chemotherapy or immunosuppressants
- Subjects who are pregnant and/or breastfeeding
- Subjects with tape adhesive allergies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NMSC Imaging
Optical Frequency Domain Imaging (OFDI) will be used to look at non melanoma skin cancer (NMSC) lesion(s).
|
Imaging of skin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful imaging of lesion
Time Frame: After completion of imaging session
|
Images acquired of NMSC
|
After completion of imaging session
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Benjamin Vakoc, PhD, Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012P002430
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Melanoma Skin Cancer (NMSC)
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Skin Analytics LimitedInnovate UKCompleted
-
University of PennsylvaniaUniversity of Missouri-Columbia; Oregon Health and Science University; Stanford... and other collaboratorsCompletedSkin Cancer, Non-Melanoma | Mohs Micrographic Surgery | Skin Cancer MelanomaUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingSkin Cancer, Non-MelanomaFrance
-
Technische Universität DresdenCompletedNon-melanoma Skin CancerGermany
-
Assiut UniversityCompleted
-
Skin Analytics LimitedInnovate UKCompleted
-
Xoft, Inc.Enrolling by invitationNon-melanoma Skin CancerUnited States
-
University of Colorado, DenverWithdrawn
Clinical Trials on OFDI
-
Massachusetts General HospitalNational Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationCoronary ArteriosclerosisUnited States
-
Massachusetts General HospitalCompleted
-
Massachusetts General HospitalEnrolling by invitationHealthy | Celiac DiseaseUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedAtrial FibrillationUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedEosinophilic Esophagitis | Barrett's EsophagusUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingBarrett Esophagus | Barretts Esophagus With DysplasiaUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingBarrett's EsophagusUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBarrett's EsophagusUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingBarrett's EsophagusUnited States
-
Massachusetts General HospitalCompletedBarrett's EsophagusUnited States